Reason #1 Your Dose May Not Be Optimized Quick Answer Semaglutide requires careful titration to reach therapeutic effectiveness
A 2023 randomized trial showed average weight loss of 35% at 0.25 mg weekly, and 1015% at 2.4 mg weekly, suggesting that individual threshold variation is substantial
Medical Disclaimer: The information provided in this article is for educational and reference purposes only and does not constitute medical advice or be used as a substitute for professional medical diagnosis, treatment, or advice
Martin Holst Lange, chief scientific officer and executive vice president of research and development at Novo Nordisk, said: "Based on the significant unmet need in Alzheimer's disease as well as a number of indicative data points, we felt we had a responsibility to explore semaglutide's potential, despite a low likelihood of success
Macronutrient Priorities Protein has already been discussed extensively